JMP Securities Begins Coverage on Context Therapeutics (NASDAQ:CNTX)

Research analysts at JMP Securities initiated coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research note issued on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $4.00 price target on the stock. JMP Securities’ target price would indicate a potential upside of 230.58% from the company’s previous close.

CNTX has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd. D. Boral Capital started coverage on Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $6.33.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $1.21 on Wednesday. The company has a market cap of $90.75 million, a price-to-earnings ratio of -1.33 and a beta of 2.10. Context Therapeutics has a 1 year low of $0.89 and a 1 year high of $2.75. The stock’s 50 day simple moving average is $1.50 and its two-hundred day simple moving average is $1.93.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTX. Y Intercept Hong Kong Ltd purchased a new position in shares of Context Therapeutics during the third quarter valued at approximately $89,000. Renaissance Technologies LLC boosted its holdings in Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares during the period. State Street Corp boosted its holdings in Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares during the period. Affinity Asset Advisors LLC grew its position in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after acquiring an additional 1,290,323 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new stake in Context Therapeutics in the third quarter worth $3,689,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.